These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 27363012)

  • 1. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
    Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
    Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/β-catenin pathway.
    Lu W; Lin C; Roberts MJ; Waud WR; Piazza GA; Li Y
    PLoS One; 2011; 6(12):e29290. PubMed ID: 22195040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saikosaponin D from Radix Bupleuri suppresses triple-negative breast cancer cell growth by targeting β-catenin signaling.
    Wang J; Qi H; Zhang X; Si W; Xu F; Hou T; Zhou H; Wang A; Li G; Liu Y; Fang Y; Piao HL; Liang X
    Biomed Pharmacother; 2018 Dec; 108():724-733. PubMed ID: 30248540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preferential Inhibition of Wnt/β-Catenin Signaling by Novel Benzimidazole Compounds in Triple-Negative Breast Cancer.
    Gangrade A; Pathak V; Augelli-Szafran CE; Wei HX; Oliver P; Suto M; Buchsbaum DJ
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide.
    Lu L; Dong J; Wang L; Xia Q; Zhang D; Kim H; Yin T; Fan S; Shen Q
    Oncogene; 2018 Sep; 37(39):5292-5304. PubMed ID: 29855616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway.
    Xie W; Zhang Y; He Y; Zhang K; Wan G; Huang Y; Zhou Z; Huang G; Wang J
    Int J Biochem Cell Biol; 2018 Oct; 103():45-55. PubMed ID: 30096373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardamonin, a chalcone, inhibits human triple negative breast cancer cell invasiveness by downregulation of Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
    Shrivastava S; Jeengar MK; Thummuri D; Koval A; Katanaev VL; Marepally S; Naidu VGM
    Biofactors; 2017 Mar; 43(2):152-169. PubMed ID: 27580587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
    Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
    Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
    J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
    BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced lncRNA Aim enhances the malignant invasion of triple-negative breast cancer cells mainly by activating Wnt/β-catenin/mTOR/PI3K signaling.
    Liu L; Yu D; Shi H; Li J; Meng L
    Pharmazie; 2017 Oct; 72(10):599-603. PubMed ID: 29441885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
    Arend RC; Londoño-Joshi AI; Samant RS; Li Y; Conner M; Hidalgo B; Alvarez RD; Landen CN; Straughn JM; Buchsbaum DJ
    Gynecol Oncol; 2014 Jul; 134(1):112-20. PubMed ID: 24736023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
    Monin MB; Krause P; Stelling R; Bocuk D; Niebert S; Klemm F; Pukrop T; Koenig S
    J Surg Res; 2016 Jun; 203(1):193-205. PubMed ID: 27338550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
    Shen H; Yan W; Yuan J; Wang Z; Wang C
    J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells.
    Maubant S; Tesson B; Maire V; Ye M; Rigaill G; Gentien D; Cruzalegui F; Tucker GC; Roman-Roman S; Dubois T
    PLoS One; 2015; 10(4):e0122333. PubMed ID: 25848952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxytyrosol inhibits cancer stem cells and the metastatic capacity of triple-negative breast cancer cell lines by the simultaneous targeting of epithelial-to-mesenchymal transition, Wnt/β-catenin and TGFβ signaling pathways.
    Cruz-Lozano M; González-González A; Marchal JA; Muñoz-Muela E; Molina MP; Cara FE; Brown AM; García-Rivas G; Hernández-Brenes C; Lorente JA; Sanchez-Rovira P; Chang JC; Granados-Principal S
    Eur J Nutr; 2019 Dec; 58(8):3207-3219. PubMed ID: 30460610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganoderma lucidum (Reishi) suppresses proliferation and migration of breast cancer cells via inhibiting Wnt/β-catenin signaling.
    Zhang Y
    Biochem Biophys Res Commun; 2017 Jul; 488(4):679-684. PubMed ID: 28427938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
    Nasser F; Moussa N; Helmy MW; Haroun M
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P; Carlson JH; Wu H; Marcus A; Leyland-Jones B; Dey N
    Oncotarget; 2016 Jul; 7(28):43124-43149. PubMed ID: 27281609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.